172 related articles for article (PubMed ID: 16612334)
1. Osteoporosis in hemodialysis patients revisited by bone histomorphometry: a new insight into an old problem.
Barreto FC; Barreto DV; Moyses RM; Neves CL; Jorgetti V; Draibe SA; Canziani ME; Carvalho AB
Kidney Int; 2006 May; 69(10):1852-7. PubMed ID: 16612334
[TBL] [Abstract][Full Text] [Related]
2. Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANK-L) serum levels in patients on chronic hemodialysis.
Gonnelli S; Montagnani A; Caffarelli C; Cadirni A; Campagna MS; Franci MB; Lucani B; Gaggiotti E; Nuti R
J Endocrinol Invest; 2005 Jun; 28(6):534-9. PubMed ID: 16117195
[TBL] [Abstract][Full Text] [Related]
3. Using the ratio of serum osteoprotegerin ligand to osteoprotegerin to evaluate renal osteodystrophy in dialysis patients.
Grzegorzewska AE; Mlot M
Adv Perit Dial; 2005; 21():188-93. PubMed ID: 16686316
[TBL] [Abstract][Full Text] [Related]
4. Hepatic osteodystrophy: does the osteoprotegerin/receptor activator of nuclear factor-kB ligand system play a role?
Gaudio A; Lasco A; Morabito N; Atteritano M; Vergara C; Catalano A; Fries W; Trifiletti A; Frisina N
J Endocrinol Invest; 2005 Sep; 28(8):677-82. PubMed ID: 16277162
[TBL] [Abstract][Full Text] [Related]
5. Ratio of cyclase activating and cyclase inactive parathormone (CAP/CIP) in dialysis patients: correlations with other markers of bone disease.
Grzegorzewska AE; Młot M
Rocz Akad Med Bialymst; 2004; 49():190-2. PubMed ID: 15631341
[TBL] [Abstract][Full Text] [Related]
6. Plasma osteoprotegerin is associated with mortality in hemodialysis patients.
Morena M; Terrier N; Jaussent I; Leray-Moragues H; Chalabi L; Rivory JP; Maurice F; Delcourt C; Cristol JP; Canaud B; Dupuy AM
J Am Soc Nephrol; 2006 Jan; 17(1):262-70. PubMed ID: 16280472
[TBL] [Abstract][Full Text] [Related]
7. Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle.
Morabito N; Gaudio A; Lasco A; Atteritano M; Pizzoleo MA; Cincotta M; La Rosa M; Guarino R; Meo A; Frisina N
J Bone Miner Res; 2004 May; 19(5):722-7. PubMed ID: 15068494
[TBL] [Abstract][Full Text] [Related]
8. Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34).
Buxton EC; Yao W; Lane NE
J Clin Endocrinol Metab; 2004 Jul; 89(7):3332-6. PubMed ID: 15240611
[TBL] [Abstract][Full Text] [Related]
9. Bone cytokines and renal osteodystrophy in peritoneal dialysis patients.
Mesquita M; Wittersheim E; Demulder A; Dratwa M; Bergmann P
Adv Perit Dial; 2005; 21():181-4. PubMed ID: 16686314
[TBL] [Abstract][Full Text] [Related]
10. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
Avbersek-Luznik I; Balon BP; Rus I; Marc J
Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031
[TBL] [Abstract][Full Text] [Related]
11. Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment.
Rogers A; Eastell R
J Clin Endocrinol Metab; 2005 Nov; 90(11):6323-31. PubMed ID: 16105967
[TBL] [Abstract][Full Text] [Related]
12. The RANKL/OPG system and bone mineral density in patients with chronic liver disease.
Moschen AR; Kaser A; Stadlmann S; Millonig G; Kaser S; Mühllechner P; Habior A; Graziadei I; Vogel W; Tilg H
J Hepatol; 2005 Dec; 43(6):973-83. PubMed ID: 16143421
[TBL] [Abstract][Full Text] [Related]
13. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index.
Terpos E; Szydlo R; Apperley JF; Hatjiharissi E; Politou M; Meletis J; Viniou N; Yataganas X; Goldman JM; Rahemtulla A
Blood; 2003 Aug; 102(3):1064-9. PubMed ID: 12689925
[TBL] [Abstract][Full Text] [Related]
14. Serum markers of bone turnover in dialyzed patients grouped by level of intact parathyroid hormone.
Grzegorzewska AE; Mlot-Michalska M
Adv Perit Dial; 2006; 22():203-6. PubMed ID: 16983970
[TBL] [Abstract][Full Text] [Related]
15. Effects of the phytoestrogen genistein on the circulating soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin system in early postmenopausal women.
Crisafulli A; Altavilla D; Squadrito G; Romeo A; Adamo EB; Marini R; Inferrera MA; Marini H; Bitto A; D'Anna R; Corrado F; Bartolone S; Frisina N; Squadrito F
J Clin Endocrinol Metab; 2004 Jan; 89(1):188-92. PubMed ID: 14715848
[TBL] [Abstract][Full Text] [Related]
16. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients.
Kraj M; Owczarska K; Sokołowska U; Centkowski P; Pogłód R; Kruk B
Arch Immunol Ther Exp (Warsz); 2005; 53(5):454-64. PubMed ID: 16314829
[TBL] [Abstract][Full Text] [Related]
17. Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients.
Haas M; Leko-Mohr Z; Roschger P; Kletzmayr J; Schwarz C; Domenig C; Zsontsich T; Klaushofer K; Delling G; Oberbauer R
Am J Kidney Dis; 2002 Mar; 39(3):580-6. PubMed ID: 11877577
[TBL] [Abstract][Full Text] [Related]
18. Soluble receptor activator of nuclear factor- kappaB Ligand (sRANKL)/osteoprotegerin balance in ageing and age-associated diseases.
Pulsatelli L; Dolzani P; Silvestri T; Caraceni P; Facchini A; Ravaglia G; Salvarani C; Melicòni R; Mariani E
Biogerontology; 2004; 5(2):119-27. PubMed ID: 15105586
[TBL] [Abstract][Full Text] [Related]
19. Serum leptin in dialysis renal osteodystrophy.
Coen G; Ballanti P; Fischer MS; Balducci A; Calabria S; Colamarco L; Di Zazzo G; Lifrieri F; Manni M; Sardella D; Nofroni I; Bonucci E
Am J Kidney Dis; 2003 Nov; 42(5):1036-42. PubMed ID: 14582047
[TBL] [Abstract][Full Text] [Related]
20. Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study.
Bernstein CN; Sargent M; Leslie WD
Inflamm Bowel Dis; 2005 Apr; 11(4):325-30. PubMed ID: 15803021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
